Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing shouldn’t feel like decoding lab notes. Vistagen Therapeutics’ SEC documents run deep with neuroscience data, stem-cell platform details, and pivotal trial timelines—critical facts that can overwhelm even seasoned analysts.
Our platform solves that problem in three steps. First, real-time alerts surface every Vistagen Therapeutics insider trading Form 4 transactions notice, so you can track executive stock moves as they happen. Second, AI-powered summaries turn the 200-page Vistagen Therapeutics annual report 10-K simplified and each Vistagen Therapeutics quarterly earnings report 10-Q filing into a few clear paragraphs, highlighting cash runway, R&D spend, and key pipeline milestones. Third, expert context links each disclosure to what matters for an R&D-heavy business—whether it’s a licensing update in an 8-K material events explained alert or voting matters in the Vistagen Therapeutics proxy statement executive compensation section.
- Instant dashboards for Vistagen Therapeutics Form 4 insider transactions real-time
- AI commentary that answers common questions like “What does this toxicology update mean?” or “How do I read Vistagen Therapeutics SEC filings explained simply?”
- Side-by-side metrics to speed up Vistagen Therapeutics earnings report filing analysis
Whether you’re comparing segment spend across quarters or monitoring Vistagen Therapeutics executive stock transactions Form 4, Stock Titan turns raw disclosures into actionable intelligence—so you spend minutes, not hours, understanding Vistagen’s next scientific milestone.
Form 4: Director Joanne Curley received a grant of non-qualified stock options in Vistagen Therapeutics, Inc. (VTGN). The options were granted on 09/09/2025 with an exercise price of $3.61 and cover 17,600 shares of common stock. The options vest in twelve equal monthly installments beginning on the grant date and expire on 09/09/2035. Following the transaction, Ms. Curley beneficially owns 17,600 options directly. The report was filed by an attorney-in-fact on 09/11/2025.
Insider option grant reported for Vistagen Therapeutics (VTGN). Director Ann Cunningham was granted a non-qualified stock option to buy 17,600 shares of common stock at an exercise price of $3.61 per share. The option vests in twelve equal monthly installments beginning on the grant date and is exercisable through 09/09/2035. Following the reported transaction, the reporting person beneficially owns 17,600 shares subject to the option as direct ownership. The grant was made under the company's Amended and Restated 2019 Omnibus Equity Incentive Plan.
Janus Henderson Group plc and an affiliated fund reported a significant passive stake in Vistagen Therapeutics, Inc. The filing shows Janus Henderson Group plc (through its entities) beneficially owns 4,165,767 shares, representing 13.6% of the class, with shared voting and dispositive power over those shares. Separately, Janus Henderson Biotech Innovation Master Fund Ltd reports beneficial ownership of 3,575,276 shares, representing 11.7% of the class.
The Schedule 13G indicates these positions are held in the ordinary course of business and not for the purpose of influencing control. The filing identifies the issuer's principal office in South San Francisco and lists Janus Henderson entities as registered investment advisers or related subsidiaries involved in managing the holdings. Signatures are provided by the Head of North America Compliance, dated 09/08/2025.
Great Point Partners and two principals report beneficial ownership of 2,055,834 shares of Vistagen Therapeutics (VTGN), representing 6.59% of the outstanding common stock. The reported interest consists of warrants exercisable into common stock and is calculated using 29,157,733 shares outstanding as reported by the issuer.
The filing is a joint Schedule 13G/A by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, each disclosing shared voting and dispositive power over 2,055,834 shares. The warrants contain a Beneficial Ownership Cap that limits exercise so the holder would not exceed 9.99% ownership, and the reporting persons disclaim beneficial ownership of underlying shares except to the extent of pecuniary interest.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
